Division of Geriatric Medicine and Center for Sleep and Respiratory Neurobiology, 3615 Chestnut St., Philadelphia, PA 19104, USA.
J Clin Sleep Med. 2010 Dec 15;6(6):572-80.
To evaluate the effectiveness of ramelteon, a melatonin receptor agonist, for the treatment of insomnia in older adults starting auto-titrating positive airway pressure (APAP) therapy for sleep apnea.
A parallel group, randomized, double-blind, placebo-controlled pilot effectiveness clinical trial. The study enrolled 21 research study participants who were ≥ 60 years old and had obstructive sleep apnea, defined by an apnea-hypopnea index (AHI) ≥ 5 events/h, with complaints of insomnia. The primary outcome measure was change in sleep onset latency determined from polysomnography at 4 weeks. Research study participants, all of whom were starting on APAP, were randomized to ramelteon 8 mg (n = 8) or placebo (n = 13).
Ramelteon treatment was associated with a statistically significant difference in sleep onset latency (SOL) as measured by polysomnography of 28.5 min (± 16.2 min) compared to placebo (95% C.I. 8.5 min to 48.6 min, effect size 1.35, p = 0.008). This was due to a 10.7 (± 17.0) min SOL reduction in the ramelteon arm and a 17.8 (± 23.5) min SOL increase in the placebo arm. No change was noted in subjective sleep onset latency (-1.3 min, ± 19.3 min, 95% C.I.: -21.4 min to 18.7 min). No statistically significant changes were noted in the AHI, sleep efficiency (polysomnography and self-report), APAP adherence, Pittsburgh Sleep Quality Index global score, or Epworth Sleepiness Scale score when comparing ramelteon vs. placebo. Four adverse events occurred in the ramelteon arm and 2 in the placebo arm; none were considered to be related to treatment.
Ramelteon was effective in improving objective, but not subjective, sleep onset latency even in older adults who were starting APAP therapy for sleep apnea. Further research is warranted in examining the role of ramelteon in the care of older adults with insomnia symptoms and sleep apnea.
评估褪黑素受体激动剂雷美替胺治疗阻塞性睡眠呼吸暂停患者自动滴定正压通气(APAP)治疗起始时失眠的疗效。
一项平行组、随机、双盲、安慰剂对照的初步有效性临床试验。该研究纳入了 21 名研究参与者,年龄均≥60 岁,有阻塞性睡眠呼吸暂停,定义为呼吸暂停低通气指数(AHI)≥5 次/小时,伴有失眠症状。主要结局指标为 4 周时多导睡眠图测定的睡眠潜伏期变化。所有参与者均开始接受 APAP 治疗,随机分为雷美替胺 8mg 组(n=8)或安慰剂组(n=13)。
雷美替胺治疗与多导睡眠图测量的睡眠潜伏期(SOL)有统计学显著差异,为 28.5 分钟(±16.2 分钟),而安慰剂组为 95%置信区间为 8.5 分钟至 48.6 分钟,效应大小为 1.35,p=0.008)。这是由于雷美替胺组 SOL 减少了 10.7(±17.0)分钟,而安慰剂组 SOL 增加了 17.8(±23.5)分钟。主观睡眠潜伏期无变化(-1.3 分钟,±19.3 分钟,95%置信区间:-21.4 分钟至 18.7 分钟)。与安慰剂相比,雷美替胺组的 AHI、睡眠效率(多导睡眠图和自我报告)、APAP 依从性、匹兹堡睡眠质量指数总分或 Epworth 嗜睡量表评分均无统计学显著变化。雷美替胺组有 4 例不良事件,安慰剂组有 2 例,均认为与治疗无关。
雷美替胺可有效改善客观睡眠潜伏期,即使在开始接受阻塞性睡眠呼吸暂停患者 APAP 治疗的老年患者中也是如此。需要进一步研究雷美替胺在治疗有失眠症状和睡眠呼吸暂停的老年患者中的作用。